[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"shivering\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:shivering":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,69,96,117,142,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269",false,"NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","18 Years","40 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[27,28,29,30,31,32],"Ondansetron","Lozenge","Intravenous","Prevention","Shivering","Cesarean Section","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-23","ACTUAL",{"date":39,"type":37},"2026-04-11",{"date":41,"type":21},"2026-08-30",{"name":43,"class":44},"Tanta University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100630597","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-tonsillectomy-100630597","NCT07489742","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Children undergoing tonsillectomy under general anesthesia.\n\nExclusion Criteria:\n\n* Allergy to ondansetron.\n* History of sleep apnea.\n* Cardiac and respiratory diseases.\n* Upper respiratory tract infection.\n* Taking corticosteroids.","ALL","4 Years","15 Years",{"count":57,"type":21},210,[24],"This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in tonsillectomy.",[27,28,29,31,61],"Tonsillectomy","2026-03-25",{"date":64,"type":37},"2026-03-27",{"date":62,"type":37},{"date":67,"type":21},"2026-09-01",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100418584","phase-4-dexmedetomidine-for-intraoperative-shivering-in-scheduled-elective-cesarean-delivery-100418584","NCT04730609","Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery","Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose","Inclusion Criteria:\n\n* Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique.\n\nExclusion Criteria:\n\n* Any contraindication to spinal anesthesia technique.\n* Allergy or intolerance to dexmedetomidine or clonidine.\n* Oral temperature \\\u003C 36° Celsius prior to procedure.\n* Unable to give personal consent.\n* PPROM or concern for infection (e.g., chorioamnionitis).\n* Conversion to General Anesthesia prior to randomization.\n* Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.",{"count":77,"type":21},40,[79],"PHASE4","The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.",[31,82],"Dose Finding Study",[31,84,85,86],"Cesarean Delivery","Dexmedetomidine","Dosing","2025-09-05",{"date":89,"type":37},"2025-09-11",{"date":91,"type":37},"2021-09-21",{"date":93,"type":21},"2026-08",{"name":95,"class":44},"Mayo Clinic",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":45},"100604848","phase-4-comparative-study-between-the-efficacy-of-intravenous-hydrocortisone-and-intravenous-dexmedetomidine-for-prevention-of-postoperative-shivering-after-general-anaesthesia-for-abdominal-surgeries-100604848","NCT07154849","Comparative Study Between the Efficacy of Intravenous Hydrocortisone and Intravenous Dexmedetomidine for Prevention of Postoperative Shivering After General Anaesthesia for Abdominal Surgeries","Inclusion Criteria: any patient undergoing abdominal surgery ASAI or II.\n\n\\-\n\nExclusion Criteria:\n\n* Patients with known neurologic and psychiatric illness.\n* Uncontrolled diabetic patients.\n* Patients on long term steroid therapy.\n* Allergy to any of the drugs used in the study.\n* Pregnancy and lactation.\n* Hypo or hyperthyroidism.","65 Years",{"count":104,"type":21},70,[79],"The aim and purpose of this study is to compare the efficacy of intravenous hydrocortisone and intravenous dexmedetomidine for prevention and treatment of postoperative shivering after general anesthesia for abdominal surgeries.",[31],"2025-09-03",{"date":110,"type":37},"2025-09-04",{"date":112,"type":37},"2024-11-11",{"date":114,"type":21},"2025-12-20",{"name":116,"class":44},"Ain Shams University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100537895","the-effect-of-warmed-socks-developed-as-wearable-technology-on-hypothermia-thermal-comfort-perception-and-shivering-100537895","NCT06283771","The Effect of Warmed Socks Developed as Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering","The Effect of Warmed Socks Developed as Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering in Healthy Volunteers","Inclusion Criteria:\n\n* -Written and verbal permission to participate in the study was obtained,\n* No communication problems,\n* Speaks and understands Turkish,\n* Non-hypothermic,\n* Not diagnosed with a chronic disease,\n* Not allergic to sock material,\n* No peripheral vascular disease,\n* Without a device that sends electric current into the body (pacemaker, etc.),\n* Healthy volunteers with a body mass index within normal limits (18.5-24.9 kg\u002Fm2).\n\nExclusion Criteria:\n\n* Written and verbal permission to participate in the research could not be obtained,\n* Communication problems,\n* Speaking Turkish but not understanding it,\n* Diagnosed with a chronic disease,\n* Hypothermic,\n* Peripheral vascular disease,\n* Allergic to sock material,\n* A person with a device (pacemaker, etc.) that sends electric current into the body,\n* Healthy volunteers with a body mass index not within normal limits (\\\u003C18.5 kg\u002Fm2- \\>25 kg\u002Fm2)",true,{"count":104,"type":21},[24],"In this study, it is aimed to reveal the effect of the use of heated socks to be developed as wearable technology by providing temperature control on body temperature, comfort perception level and shivering development in healthy volunteers and this purpose constitutes the unique value of the project. The research was planned as a prospective, two-arm (1:1), randomized controlled, double-blind study. The population of the study will consist of 4th year nursing students consisting of an average of 250 people who will enroll in the fall semester of the 2024-2025 academic year. As a result of the power analysis performed in the G\\*Power program, the sample will consist of 70 healthy volunteers, at least 35 in each group. In the study, data will be collected with the \"Descriptive Characteristics Form\" and \"Hypothermia Monitoring Form (Shivering Level Diagnosis Form and Temperature Comfort Perception Scale)\" which includes the descriptive information of healthy volunteers. Healthy volunteers will fill out the \"Introductory Characteristics Form\" and \"Hypothermia Monitoring Form\" before being taken to the Faculty of Nursing Skills Laboratory for the application. Before the volunteers are taken to the single rooms in the laboratory, the environment will be cooled for 30 minutes with the air conditioner in the room so that the temperature is 21oC. The study group will wear socks developed with wearable technology and the control group will wear socks with the same appearance. The healthy volunteer will be asked to lie motionless on the bed for 60 minutes in a single room. Body temperature (with Braun tympanic thermometer), shivering level and temperature comfort perception will be recorded on the \"Hypothermia Monitoring Form\" when all healthy volunteers are taken to the Skills Laboratory, at 15 minutes, 30 minutes and 60 minutes, and when they leave the laboratory. The research data will be analyzed in a computer environment. Descriptive variables of healthy volunteers included in the study will be expressed as mean±standard deviation and median (maximum minimum), percentage and frequency. Changes in body temperature measurements obtained after wearing socks to be developed with wearable technology, repeated measurements, analysis of variance (Repeated ANOVA) if parametric, Friedman test if non-parametric, and post-hoc test will be used in intra-group multiple comparison analysis as further analy",[129,130,31,131],"Wearable Technology","Hypothermia","Thermal Comfort Perception","NOT_YET_RECRUITING","2025-09-02",{"date":135,"type":37},"2025-09-09",{"date":137,"type":21},"2025-12-15",{"date":139,"type":21},"2026-09-15",{"name":141,"class":44},"Tarsus University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100570509","effect-of-preemptive-education-on-the-incidence-of-maternal-intraoperative-shivering-in-elective-cesarean-delivery-100570509","NCT06708169","Effect of Preemptive Education on the Incidence of Maternal Intraoperative Shivering in Elective Cesarean Delivery","Effect of Preemptive Education on the Incidence of Maternal Intraoperative Shivering in Elective Cesarean Delivery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 19 years or older\n* Gestational age 37 weeks or above\n* Elective surgey\n\nExclusion Criteria:\n\n* Emergency surgery\n* Any sign of onset of labor\n* Difficulty with communication\n* Contraindications of spinal anesthesia\n* Pre-eclampsia","19 Years",{"count":151,"type":21},130,[24],"The goal of this study is to learn about the effect of preemptive education on reducing intraoperative maternal shivering in elective cesarean delivery. The main question it aims to answer is:\n\nDoes preemptive education by anesthesiologists reduce intraoperative maternal shivering in elective cesarean delivery?",[31,155],"Spinal Anesthesia","2025-05-12",{"date":158,"type":37},"2025-05-15",{"date":160,"type":37},"2024-12-09",{"date":162,"type":21},"2026-08-31",{"name":164,"class":44},"Seoul National University Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":124,"sex":53,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":176,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":45},"100498046","safe-brain-initiative-operationalizing-precision-anaesthesia-100498046","NCT05765162","Safe Brain Initiative, Operationalizing Precision Anaesthesia","Safe Brain Initiative - Dedicated to Advancing Anaesthesia and Perioperative Personalised Care Towards Precision Anaesthesia Care. A Continuous Quality Improvement Initiative.","SBI","Inclusion Criteria:\n\n• All patients from age ≥18\n\nExclusion Criteria:\n\n• All patients from age \\\u003C18","100 Years",{"count":175,"type":21},15000,"5 Years","OBSERVATIONAL","Perioperatively, patients experience an unnecessarily high level of side effects associated with their treatment. These side effects include nausea, severe pain, anxiety, and stress. Moreover, many patients develop postoperative delirium (POD) and neurocognitive dysfunctions, often resulting in long-term cognitive impairment, decreased quality of life, and increased mortality. However, physicians, nurses and their institutions do not receive structured feedback regarding these aspects of each patient's well-being. They may therefore be unable to engage in the essential cause-and-effect learning necessary to evaluate and consecutively reduce such side effects.\n\nEffective guidelines conform prevention is the proven key to shielding our patients from adverse Outcomes. The Safe Brain Initiative's high-quality routine data-for-action is a sword and accelerator for moving towards patient-centred, precision care. Thus, establishing a foundation for value-based and patient-centred healthcare development.\n\nHowever, a turnkey real-world solution is challenging to develop and implement and requires substantial resources. As a result, such solutions are usually beyond the scope of a single institution. The SBI platform provides high-quality, real-world data to bridge this gap. It allows monitoring and in-depth analysis of cause and effect in the day-to-day routine of individuals, departments, and institutions.\n\nThe SBI's approach is continuously improved and updated. An organization called the SBI Global Society oversees the quality and precision of science through experts in the field. At SBI Hospitals and Flagship centres, Masterclasses are conducted and can be attended alongside clinical immersions.\n\nSBI Solutions manages, develops, and provides technical and service support for the Safe Brain Initiative. Its service guarantees the professional and GDPR conform management of data handling and storage as well as the user-friendly functionality of the SBI-Dashboard solutions.",[180,181,182,183,184,185,31,186,187,188,189,190,191,192,193,194,195],"Neurocognitive Disorders","Post Operative Delirium","Pain","Nausea","Vomiting","Wellbeing","Anxiety","Stress","Agitation,Psychomotor","Sedation Complication","Thirst","Satisfaction, Patient","Temperature Change, Body","Fasting","Sore-throat","Hearing and Vision Loss","2024-06-05",{"date":198,"type":37},"2024-06-07",{"date":200,"type":37},"2021-12-01",{"date":202,"type":21},"2026-01-01",{"name":204,"class":44},"University of Southern Denmark"]